Evidence map›Paper›PMID 42261376›Full record

ArticleHemaSphere2026

Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis.

Francesco Pegoraro, Francois Chalard, Dmitry Evseev, Mohamed Barkaoui, Solenne Le Louet, Julian Thalhammer, Nathalie Aladjidi, Alexandra Salmon, Perrine Marec-Berard, Stefania Gaspari and 29 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Francesco PegoraroDepartment of Experimental and Clinical Medicine University of Florence Florence Italy.ORCID https://orcid.org/0000-0002-4954-5744
Francois ChalardRadiology Department Trousseau Hospital Paris France.
Dmitry EvseevDepartment of Hematopoietic Stem Cell Transplantation Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology Moscow Russia.
Mohamed BarkaouiFrench Reference Center for Langerhans Cell Histiocytosis Trousseau Hospital Paris France.
Solenne Le LouetFrench Reference Center for Langerhans Cell Histiocytosis Trousseau Hospital Paris France.
Julian ThalhammerDepartment of Pediatric Hematology Lille University Hospital Lille France.
Nathalie AladjidiDepartment of Pediatric Hematology and Oncology Bordeaux University Hospital Bordeaux France.
Alexandra SalmonDepartment of Pediatric Hematology and Oncology Strasbourg University Hospital Strasbourg France.
Perrine Marec-BerardDepartment of Paediatric Oncology Léon-Bérard Centre Lyon France.
Stefania GaspariPediatric Hematology Oncology, Cellular and Gene Therapy Bambino Gesù Children's Hospital IRCCS Rome Italy.
Carmela De FuscoDepartment of Pediatric Oncology AORN Santobono-Pausilipon Naples Italy.
Irene TrambustiDepartment of Experimental and Clinical Medicine University of Florence Florence Italy.
Antonio VerricoNeuro-Oncology Unit IRCCS Istituto Giannina Gaslini Genoa Italy.
Anna RaciborskaDepartment of Oncology and Surgical Oncology for Children and Youth Institute of Mother and Child Warsaw Poland.
Karel SvojgrDepartment of Pediatric Hematology and Oncology University Hospital Motol and 2nd Faculty of Medicine Prague Czech Republic.
Zdenka KřenováDepartment of Pediatric Hematology and Oncology University Hospital Brno Brno Czech Republic.
Olga SlaterDepartment of Paediatric Hemato-Oncology Great Ormond Street Hospital London UK.
Gerard MillenDepartment of Paediatric Oncology Birmingham Children's Hospital Birmingham UK.
Myriam Ben ArushPediatric Oncology Rambam Medical Center Haifa Israel.
Dana Ashkenazi LustigPediatric Oncology Rambam Medical Center Haifa Israel.
Tatiana Von Bahr GreenwoodChildhood Cancer Research Unit, Department of Women's and Children's Health Karolinska Institute Stockholm Sweden.
Caroline HutterSt. Anna Children's Cancer Research Institute Vienna Austria.
Itziar AstigarragaHospital Universitario de Cruces, IIS Biobizkaia Universidad País Vasco UPV/EHU, Unidad de Hematología y Oncología Pediátrica Barakaldo Spain.
Mónica López-DuartePediatric Hematology Unit, Hematology Department Hospital de Valdecilla-IDIVAL Santander Spain.
Lorena Valero-ArresePediatric Haematology and Oncology Division Vall d'Hebron University Hospital Barcelona Spain.
María José Ortega AcostaPediatric Haematology Unit Virgen de las Nieves University Hospital Granada Spain.
Cor van den BosDepartment of Hemato-Oncology Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands.
Leonie NaeijeDepartment of Hemato-Oncology Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands.
Daniel Martin-MunozDepartment of Neuroradiology Karolinska University Hospital Stockholm Sweden.
Anna PerroneRadiology Unit Meyer Children's Hospital IRCCS Firenze Italy.
Marzia MortillaNeuroradiology Meyer Children's Hospital IRCCS Firenze Italy.
Olivier FelicianAix-Marseille University, INSERM, INS Institut de Neurosciences des Systèmes Marseille France.
Ahmed IdbaihNeurology Unit Pitié Salpêtrière University Hospital Paris France.
Sébastien HéritierFrench Reference Center for Langerhans Cell Histiocytosis Trousseau Hospital Paris France.
Vasanta NanduriDepartment of Paediatrics Watford General Hospital Watford UK.
Milen MinkovSt. Anna Children's Cancer Research Institute Vienna Austria.
Jan-Inge HenterChildhood Cancer Research Unit, Department of Women's and Children's Health Karolinska Institute Stockholm Sweden.
Elena SieniDepartment of Hematology and Oncology Meyer Children's Hospital IRCCS Florence Italy.
Jean DonadieuFrench Reference Center for Langerhans Cell Histiocytosis Trousseau Hospital Paris France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative Langerhans cell histiocytosis (ND-LCH) is a severe and debilitating complication of LCH with no effective treatment. In this study, we assessed the efficacy of MAPK inhibitors (MAPKi) in a large cohort of children with ND-LCH. We included pediatric patients with ND-LCH who received MAPKi between 2013 and 2025. Clinical and radiological responses were evaluated using validated and newly developed scoring systems. We included 60 patients and assessed the response to MAPKi in 54 (clinical

Identifiers

PMID42261376
PMCPMC13242968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.